

PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Nerlynx (neratinib)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

	Prescriber Name:		
Patient Name:	Supervising Physician:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:	THORIC.	
Group Number:	NPI:	State Lic ID:	
Address:	Address:	0.0.0 2.0 .2.	
City, State ZIP:	City, State ZIP:		
Primary Phone:	Specialty/facility name (if applicable)	ı:	
Drug Name and Strength:			
Directions / SIG:			
Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.			
Q1. For what diagnosis is this drug being prescribed (pick one)?			
☐ Early stage HER2-overexpressed/amplified breast cancer ☐ Other			
Q2. If you selected "other" in question 1, please provide documentation that use is consistent with a category 2A or higher recommendation per NCCN compendia or guidelines.			
Q3. Please provide the ICD code for the above condition.			
Q4. Is prescribing physician a hematology or oncology spe	ecialist?		
☐ Yes ☐ No			
Q5. Is Nerlynx to be used for extended adjuvant treatment	?		
☐ Yes ☐ No			
Q6. Is Nerlynx to follow trastuzumab-based therapy?			
☐ Yes ☐ No			



PRIOR AUTHORIZATION REQUEST FORM EOC ID: Nerlynx (neratinib)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

blank or illegible may delay the review process.		
Patient Name:	Prescriber Name: Supervising Physician:	
Q7. Will loperamide prophylaxis be initiated for at least	the first 56 days of treatment?	
Q8. Additional Comments:		
Prescriber Signature	Date	
□ Expedited/Urgent - By checking this box and signing al seriously jeopardize the life or health of the enrollee or the	bove, I certify that applying the standard review timeframe may ne enrollee's ability to regain maximum function	
	necessity denial. Requesting providers may speak to the SWHP medical ortunity to help impact the decision on a request before coverage has been	

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document